FlandersBio on Twitter

Follow us on Twitter

Life sciences database

Databank life sciences

in het nederlands in english

FlandersBio offers an up-to-date life sciences database with detailed information about all FlandersBio members.

FlandersBio beschikt over een geüpdate life sciences databank met een gedetailleerd overzicht van alle FlandersBio-ledenbedrijven.

reMYND

Website: http://www.remynd.com
Email:
Phone: +32 16 75 14 20
FlandersBio Member
More address details

Business Focus

reMYND actively drives the development of disease modifying treatments against Alzheimer’s disease (AD), Parkinson’s disease (PD), and diabetes, either as a Contract Research Organisation (CRO) or through its own drug discovery & development (DDD).

Tags

Company Profile

reMYND is organised along 2 fully independent business units, with a complementary focus:

  • As a CRO, reMYND offers in vivo efficacy, pharmacokinetic and toxicity testing on its proprietary mouse models for Alzheimer’s Disease, including the APP model (with the London mutation), the APPxPS1 model, and the APPxTAU model. As such, reMYND tests 3rd party treatments targeting the β-amyloid pathway for AD.
  • The in-house pipeline of the own Drug Discovery&Development consists primarily of 4 disease modifying compounds against Alzheimer’s Disease (counteracting Tau toxicity) and 2 against Parkinson’s Disease (counteracting synuclein toxicity), with a recent addition of 2 against Diabetes (counteracting IAPP toxicity). As such, reMYND develops AD treatments targeting the Tau-pathway, ensuring there is no conflict of interest with theβ -amyloid treatments of the CRO clients.The lead PD compound is planned to enter Phase I in 2010. The lead AD compound will follow one to two years later.

Science & Technology or Services

Contract Research

reMYND offers in vivo drug testing in a wide variety of Alzheimer mouse models. Testing includes biochemical analysis (determination of Aβ 40 and Aβ 42 levels in brain and CSF, APP processing blots, ...), neuropathological analysis (immunohistochemistry on β-amyloid, Thioflavin S staining of plaques, quantitation of plaques, microgliosis and astrocytosis staining, microbleedings detection, ...) and behavioral and memory studies (Morris Water Maze, novel Object Recognition Test, Open Field Test, Rotarod, Pole Test, Beam Walk, …). Different ways of compound administration are possible: intravenous, intraperitonial, intracerebroventricular, subcutaneous, intramuscular, intranasal, oral (gavage), infusion via osmotic pumps, intracranial, …

Including the early years at the University of Leuven, we have served clients for over 10 years, providing reMYND with extensive experience in all types of drug application methods for all types of Aβ treatments. In doing so, reMYND has worked for most of the top pharmaco’s and biotechs active in CNS worldwide, with several treatments now in clinical testing. As we are highly specialized, we always have cohorts of aged mice available, allowing short lead times.

In addition, reMYND sells licenses on its proprietary genotoxicity screen, which was developed for its own discovery program, as a superior alternative to other commercially available solutions addressing genotoxicity liabilities of xenobiotics.

Drug Discovery and Development

reMYND focuses entirely on disease-modifying treatments with the aim to decelerate – or even stop – neuronal degeneration. As such, we respond to a clear unmet medical need, as all marketed treatments and the majority of the products under development world-wide only treat symptoms. Clinicians would consider a decrease in disease progression by 25-30% as a major breakthrough. Still, we target a slowdown of disease progression by at least 50%. Our current lead compound in PD even fully inhibits the progression in the relevant animal models.

In discovery, hits are identified through patent protected cell-lines and validated in-vivo in proprietary animal models. reMYND has focused since 2002 on PD (targeting α-synuclein mediated cytotoxicity) and AD (targeting Tau-mediated cytotoxicity). This gives us several years ahead of competition, as the scientific community starts gradually moving from the β-amyloid pathway towards the Tau pathway as a key target against AD. In addition, our platform can be adapted to target virtually any disease associated with protein-misfolding, such as Diabetes, Huntington, and ALS.

Currently, we focus our development work on 2 compounds against PD and 4 against AD in pre-clinical development. We have demonstrated full disease-modifying proof-of-concept for drug candidate ReS9-S7 in PD with no apparent side effects observed, and early efficacy indications for 2 compound families in AD. All compounds represent small chemical entities with a drug-like chemical structure obeying Lipinski rule of 5.

Product description

in vivo testing on APP London mouse model of Alzheimers's disease, in vivo testing on APPxPS1 London mouse model of Alzheimers's disease, Radarscreen, in vivo testing on Tau and TauxPS1 mouse model of Alzheimers's disease.

Alliances

For the Drug Development&Discovery, reMYND works together with the following partners:

  • Academic Medical Center, Amsterdam, The Netherlands
  • AD Research Center, David Geffen School of Medicine at UCLA, USA
  • INSERM U815, University of Lille, France
  • Katholieke Universiteit Leuven, Belgium
  • Medical University Innsbruck, Austria
  • Philipps-University, Marburg, Germany
  • Universiteit Gent, Belgium
  • Vlaams Instituut voor Biotechnologie, Belgium
  • Vrije Universiteit Brussel, Belgium
  • University Paul Cézanne, Franc

In addition, reMYND has many alliances in place through its CRO activities, which cannot be disclosed.

Merck and BioPredic have in-licensed reMYND's Radarscreen technology for genetox testing at the early stages of lead optimisation.

reMYND is also a director at FlandersBio, and is mandated to be part of the general assembly of the Centre for Medical Innovation in Flanders.

More info

Address: Bio-incubator
Gaston Geenslaan 1
3001 Leuven
Belgium

Route: Via Google Maps
Website: http://www.remynd.com

Phone: +32 16 75 14 20
Fax: +32 16 75 14 21
Foundation date: 1/2002
Email: remynd@remynd.com

Become a Member

Listen to some testimonials from companies that are a member of FlandersBio and discover the benefits of membership

Read more

Z Life Sciences

Looking behind the scenes of the vibrant life sciences sector in Flanders!

YouTube

Biotechstockmarket

Belgian biotech on Euronext

Belgian biotech on Euronext

FlandersBio Members

GODDYN EY BioXpert Asclepia DNAlytics Emtex Agidens Life Sciences Xedev Novellas Healthcare XiTechniX Randstad Professionals Life Sciences SilveRNA Antleron Valesta ISMS MyCartis NV Movianto Belgium N.V., an Owens and Minor Company Air Consult Engineering R.I.C. BioConAct NLO, European patent and trademark attorneys Medicim Greiner Bio-One B.V.B.A. Quantum Management & Consulting PMV LBT Testing & Calibration Inovigate P95 Rousselot

View all members

Life Sciences Map

Life Sciences Map

View Life Sciences Map

Back to top

Print